Clinical Cancer Research · 2008 · 202 citations · 22 references
MedicineGynecologyOncologyChemotherapyGynecologic OncologyTumor ProgressionCancer BiomarkersImmuno-oncology BiomarkersOvarian CancerOvarian PathologyTumor MarkersOvarian Cancer BiomarkersOvarian Cancer Prognostic BiomarkersOvarian Tumor BiomarkersPlatinum SensitivityPrognostic BiomarkersPrognostic Marker AssessmentPrognostic Marker EvaluationSerum Tumor Markers
PURPOSE: To evaluate serum C-reactive protein (CRP) as prognostic variable in patients with epithelial ovarian cancer (EOC). EXPERIMENTAL DESIGN: In a multicenter study, preoperative serum CRP was evaluated in 623 patients with EOC. Results were correlated with clinical data. RESULTS: Mean (SD) preoperative serum CRP was 3.6 (4.8) mg/dL. Serum CRP was significantly associated with International Federation of Gynecologists and Obstetricians stage (P < 0.001) and postoperative residual tumor mass (P < 0.001) but not with histologic grade (P = 0.1) and type (P = 0.7), patients' age (Pearson's correlation coefficient = 0.05; P = 0.2), and serum CA 125 (Pearson's correlation coefficient = 0.02; P = 0.6). Patients with platinum-resistant EOC had significantly higher CRP serum levels compared with patients with platinum-sensitive EOC [6.0 (6.6) mg/dL versus 2.8 (3.8) mg/dL; P < 0.001]. Higher International Federation of Gynecologists and Obstetricians stage (P < 0.001), presence of postoperative residual tumor mass (P < 0.001), tumor grade (P = 0.001), serum CA 125 (P = 0.03), and serum CRP (P = 0.001) were independently associated with overall survival. Patients with serum CRP < or =1 mg/dL versus >1 mg/dL had an overall 5-year survival of 82% versus 58.5% (P < 0.001). CONCLUSION: Serum CRP can be seen as a novel, widely available independent prognostic variable of ovarian cancer.
22
The codependence of angiogenesis and chronic inflammation
Jeffrey R. Jackson, Michael Seed, Charles H. Kircher et al. · The FASEB Journal · 1997 · 699 citations
C-Reactive Protein and the Risk of Incident Colorectal Cancer
Thomas P. Erlinger · JAMA · 2004 · 538 citations · Full text
JNCI Journal of the National Cancer Institute · 2003 · 446 citations